Researchers have built personalized machine-learning models that can read an individual’s brain activity and predict how much chronic pain they are experiencing at any given moment. The work, published in Nature Neuroscience, tracked two people with chronic pain using precision longitudinal fMRI over more than half a year, producing what amounts to a unique neural fingerprint for each patient’s pain. The result challenges a long-held assumption that a single, universal brain signature could serve as a reliable pain biomarker and instead points toward a future where diagnosis and treatment are tailored person by person.
How AI Learned to Read Individual Pain
Most attempts to measure pain objectively have relied on group-level brain scans, averaging signals across many patients to find common patterns. The 2026 study took the opposite approach. By collecting repeated fMRI scans over more than six months in two individuals with chronic pain, the team gathered enough data to train personalized machine-learning decoders on each person’s whole-brain functional connectivity. Those decoders could then predict spontaneous pain intensity within each individual, a feat that group-trained models struggle to replicate because the neural circuitry encoding pain varies significantly from one person to the next.
The approach stands in deliberate contrast to earlier work. A 2020 study in Nature Medicine identified a connectivity-based signature that tracked sustained pain intensity and showed generalization across multiple studies, including clinical low back pain. That research was a significant step forward, but the 2026 findings suggest its generalized signature may miss the individual-level variation that matters most for clinical decisions. The newer paper’s conclusion is direct. Biomarkers may be individual-specific. That distinction carries real weight for anyone hoping to turn brain imaging into a diagnostic tool, and it is reinforced by the fact that access to the full article itself still requires navigating publisher authentication systems that limit how widely raw methods and data can be scrutinized.
Confirming the Signal With Brain Implants
The fMRI findings do not stand alone. A separate line of research used a fundamentally different recording method to reach a similar conclusion. In what was described as the first-in-human prediction of chronic pain state using intracranial neural biomarkers, scientists placed electrodes directly in the anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC) of patients with chronic pain. These long-term intracranial recordings were collected multiple times daily over months, and machine-learning algorithms decoded pain states from the resulting signals. The convergence of evidence across two very different measurement techniques, noninvasive fMRI and invasive electrophysiology, strengthens the case that chronic pain leaves a detectable, decodable trace in the brain.
That convergence also matters because it addresses a common criticism of neuroimaging research: that fMRI-based findings can be noisy and hard to reproduce. By triangulating the brain fingerprint concept across modalities, the combined body of work makes it harder to dismiss the signal as an artifact of one particular technology. Still, both studies involved small numbers of patients, and neither has been validated in the kind of large, diverse clinical trial that regulators would require before any tool reaches a doctor’s office. The FDA-NIH BEST Resource (housed within broader biomedical guidance) draws a clear line between exploratory biomarker signals and formally qualified biomarkers, and these pain fingerprints remain firmly in the exploratory category.
Why Personalization Changes the Clinical Calculus
The shift from group-level to individual-specific biomarkers is not just a technical refinement. It changes what clinicians could eventually do with the information. A universal pain signature offers a binary answer: pain or no pain. A personalized decoder, by contrast, could track fluctuations in a single patient’s pain over time, potentially revealing which treatments are working and which are not, without relying solely on self-report. For conditions where patients struggle to communicate their pain, or where clinicians question whether reported symptoms match underlying biology, an objective within-person measure could alter treatment decisions and help justify more aggressive interventions or, conversely, prevent unnecessary procedures.
The NIH has framed these signatures for chronic pain as a step toward developing non-addictive treatments and enabling neuromodulation approaches. That framing ties the research to the broader opioid crisis: if clinicians can see pain in the brain directly, they may be able to target it with electrical stimulation or other non-pharmacological interventions rather than prescribing drugs that carry addiction risk. In principle, a brain-based readout could also support more rigorous clinical trials, by providing an objective endpoint alongside patient-reported outcomes when testing new devices or therapies funded through programs like the BRAIN Initiative and HEAL.
What Still Stands Between Lab and Clinic
The gap between a promising research finding and a usable clinical tool remains wide. The 2026 study’s strength, its deep longitudinal tracking of individuals, is also its limitation. Scanning two people repeatedly for more than half a year is resource-intensive and not scalable in its current form. Translating personalized brain decoders into routine care would require either dramatically cheaper and faster imaging or a way to build reliable models from fewer sessions. The Figshare repository referenced in the Nature Neuroscience paper contains derived measures and model outputs that allow other researchers to verify the reported performance metrics, but it does not include raw data, which limits independent replication efforts and makes it harder to probe how well the models would generalize beyond the original participants.
There is also no cross-validation yet between the fMRI-derived fingerprints and the intracranial biomarkers in the same patients. The two approaches were tested in separate cohorts using different recording methods, so the degree to which they capture the same underlying neural process remains an open question. And the regulatory path is unclear. The clinical research ecosystem is full of promising exploratory biomarkers that never achieved formal qualification, often because they could not demonstrate consistent performance across diverse populations. Chronic pain is notoriously heterogeneous, spanning conditions from fibromyalgia to neuropathic pain and cancer-related pain, each with its own biological underpinnings. Until personalized decoders are tested across that spectrum and show that they can be calibrated reliably for many different people, they will remain powerful research tools rather than standard components of clinical decision-making.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
